KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Non-Current Debt (2016 - 2017)

Arbutus Biopharma (ABUS) has disclosed Non-Current Debt for 2 consecutive years, with $12.0 million as the latest value for Q4 2017.

  • Quarterly Non-Current Debt changed 0.0% to $12.0 million in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $12.0 million through Dec 2017, changed 0.0% year-over-year, with the annual reading at $12.0 million for FY2017, 0.0% changed from the prior year.
  • Non-Current Debt hit $12.0 million in Q4 2017 for Arbutus Biopharma, roughly flat from $12.0 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $12.0 million in Q4 2016 to a low of $12.0 million in Q4 2016.